Nephritis, Hereditary clinical trials
The registry lists 38 studies for Nephritis, Hereditary across more than 10 countries. 14 are recruiting or about to start. 28 of them are mainly about Nephritis, Hereditary (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Nephritis, Hereditary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University of Minnesota (4) · Genzyme, a Sanofi Company (3) · Stefan Lujinschi (2) · University Hospital Goettingen (2) · Eloxx Pharmaceuticals, Inc. (2) · Biogen (2) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (2) · Novartis Pharmaceuticals (2)
What is being tested here
Drugs under test in Nephritis, Hereditary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Dapagliflozin | 1 | 1 | 2 |
| ELX-02 | 1 | 0 | 2 |
| Ramipril | 1 | 1 | 2 |
| Solizmestrocel | 1 | 1 | 1 |
| Metformin | 1 | 0 | 1 |
| Sparsentan | 1 | 0 | 1 |
| Bardoxolone methyl | 0 | 2 | 2 |
| Atrasentan | 0 | 0 | 1 |
| Spironolactone | 0 | 0 | 1 |
| Setanaxib | 0 | 0 | 1 |
Drug classes tested here ACE inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 6, phase 3 first
- Sep 2027Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients · Phase 3 · University Hospital Goettingen
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
- Mar 2027Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases · Travere Therapeutics, Inc.
- Jun 2027EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety · Eloxx Pharmaceuticals, Inc.
- Sep 2027Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport) · Institut National de la Santé Et de la Recherche Médicale, France
- Nov 2027A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome · Bayer
Who these studies take
Of the 10 Nephritis, Hereditary studies recruiting now, 7 (70%) set no upper age limit and 2 (20%) stop at 75 or younger. 9 (90%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 8 (80%) | 8 (80%) |
| 18 | 9 (90%) | 9 (90%) |
| 30 | 9 (90%) | 9 (90%) |
| 40 | 8 (80%) | 8 (80%) |
| 50 | 8 (80%) | 8 (80%) |
| 65 | 8 (80%) | 8 (80%) |
| 75 | 8 (80%) | 8 (80%) |
| 85 | 7 (70%) | 7 (70%) |
Across all 38 studies, recruiting or not: 58% stop at 75 or younger and 53% at 65; 82% take children; 0% are for women only and 3% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Oct 23, 2026NCT07892651
Studies
Recruiting first, then most recently updated. Showing 38 of 38. search them.
- NEPTUNE Match StudyRecruitingNCT04571658Not applicable1 country
- MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Not yet recruitingNCT078926511 country
- Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsRecruitingNCT05944016Phase 31 country
- EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyRecruitingNCT07523581Phase 22 countries
- Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)RecruitingNCT059274671 country
- Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)RecruitingNCT075753471 country
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingNCT05003986Phase 28 countries
- ASF Alport Patient RegistryRecruitingNCT065267411 country
- Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeRecruitingNCT023788051 country
- Human Umbilical Cord Mesenchymal Stem Cells for Alport SyndromeNot yet recruitingNCT06731192Phase 2/3
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Treatment With Metformin in Chinese Children With Alport SyndromeNot yet recruitingNCT05655728Phase 4
- Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 VariantsNot yet recruitingNCT05133050Not applicable1 country
- Genotype-Phenotype Correlations in Patients With Alport SyndromeRecruitingNCT049478131 country
- A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeActive, not recruitingNCT07211685Phase 215 countries
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT)CompletedNCT06499948Phase 41 country
- Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruitingNCT04573920Phase 26 countries
- A Study to Evaluate Setanaxib in Patients With Alport SyndromeCompletedNCT06274489Phase 1/25 countries
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)CompletedNCT04937907Phase 21 country
- A Study of ELX-02 in Patients With Alport SyndromeCompletedNCT05448755Phase 22 countries
- Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)CompletedNCT06425055Phase 23 countries
- Alport Syndrome Treatments and Outcomes RegistryCompletedNCT004811301 country
- Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental GlomerulosclerosisCompletedNCT05267262Phase 26 countries
- Study of Lademirsen (SAR339375) in Patients With Alport SyndromeTerminatedNCT02855268Phase 27 countries
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINALCompletedNCT03019185Phase 2/38 countries
- An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedNCT03749447Phase 36 countries
- Effects of Dapagliflozin on Progression of Alport SyndromeActive, not recruitingNCT062268961 country
- Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeCompletedNCT00309257Phase 21 country
- Biomarker for Alport Syndrome (BioAlport)TerminatedNCT027180277 countries
- A Study of RG-012 in Subjects With Alport SyndromeCompletedNCT03373786Phase 11 country
- Efficacy and Safety Study to Delay Renal Failure in Children With Alport SyndromeCompletedNCT01485978Phase 31 country
- ATHENA: Natural History of Disease Study in Alport Syndrome PatientsCompletedNCT021368626 countries
- A Prospective Study of Microalbuminuria in Untreated Boys With Alport SyndromeCompletedNCT006225441 country
- Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility StudyCompletedNCT016962531 country
- Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesTerminatedNCT01602835
- Urinary Biomarkers of the Progression of Alport Kidney DiseaseCompletedNCT017051321 country